1h Free Analyst Time
The publisher has been monitoring the artificial heart market and it is poised to grow by $1.86 bn during 2022-2026, progressing at a CAGR of 11.8% during the forecast period. The report on the artificial heart market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current global market scenario, the latest trends and drivers, and the overall market environment. The market is driven by the increasing prevalence of HF and associated risk factors, lack of availability of organs for cardiac transplantation, and advances in VAD technology.
The artificial heart market analysis includes product segment and geographic landscape.
The artificial heart market is segmented as below:
By Product
- VAD
- TAH
By Geographical Landscape
- North America
- Europe
- Asia
- Rest of World (ROW)
This study identifies the clinical trials for the development of TAHs as one of the prime reasons driving the artificial heart market growth during the next few years. Also, focusing on the development of non-blood contacting VADs, and strategic acquisitions will lead to sizable demand in the market.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. The report on the artificial heart market covers the following areas:
- Artificial heart market sizing
- Artificial heart market forecast
- Artificial heart market industry analysis
The publisher's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading artificial heart market vendors that include Abbott Laboratories, Abiomed Inc., Berlin Heart GmbH, BiVACOR Inc., Boston Scientific Corp., Calon Cardio-Technology Ltd, CARMAT SA, Corcym Srl, CorWave SA, Edwards Lifesciences Corp., Evaheart Inc., Jarvik Heart Inc., Medtronic Plc, MyLVAD Foundation LTD., Quest Diagnostics Inc., SynCardia Systems LLC, Artivion Inc., JenaValve Technology Inc., LivaNova Plc, and Terumo Corp. Also, the artificial heart market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.
The publisher presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. The publisher's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.
Table of Contents
1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Five Forces Analysis
5 Market Segmentation by Product
6 Customer Landscape
7 Geographic Landscape
8 Drivers, Challenges, and Trends
9 Vendor Landscape
10 Vendor Analysis
11 Appendix
List of Exhibits
Executive Summary
The publisher announces the Publication of its Research Report - Global Artificial Heart Market 2022-2026The publisher recognizes the following companies as the key players in the global artificial heart market: Abbott Laboratories, Abiomed Inc., Berlin Heart GmbH, BiVACOR Inc., Boston Scientific Corp., Calon Cardio-Technology Ltd, CARMAT SA, Corcym Srl, CorWave SA, Edwards Lifesciences Corp., Evaheart Inc., Jarvik Heart Inc., Medtronic Plc, MyLVAD Foundation LTD., Quest Diagnostics Inc., SynCardia Systems LLC, Artivion Inc., JenaValve Technology Inc., LivaNova Plc, and Terumo Corp.
Commenting on the report, an analyst from the publisher said: 'The latest trend gaining momentum in the market is clinical trials for the development of TAHs.'
According to the report, one of the major drivers for this market is the increasing prevalence of HF and associated risk factors.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Abbott Laboratories
- Abiomed Inc.
- Berlin Heart GmbH
- BiVACOR Inc.
- Boston Scientific Corp.
- Calon Cardio-Technology Ltd
- CARMAT SA
- Corcym Srl
- CorWave SA
- Edwards Lifesciences Corp.
- Evaheart Inc.
- Jarvik Heart Inc.
- Medtronic Plc
- MyLVAD Foundation LTD.
- Quest Diagnostics Inc.
- SynCardia Systems LLC
- Artivion Inc.
- JenaValve Technology Inc.
- LivaNova Plc
- Terumo Corp.
